MOTS-c 10 mg

MOTS-c is a mitochondrial-derived peptide studied for its effects on metabolic regulation. Preclinical research has demonstrated that it activates AMPK, improves glucose metabolism in skeletal muscle, prevents diet-induced obesity, and enhances physical capacity in animal models. It has also been studied for potential anti-aging properties, as circulating levels decline with age.

However, human clinical evidence is limited, and no completed human safety trials have been published. MOTS-c is not an FDA-approved human pharmaceutical product.

Animal studies have shown that MOTS-c treatment reduces visceral fat accumulation and hepatic steatosis in high-fat diet-fed mice. It also inhibits genes related to lipogenesis and increases fatty acid oxidation. These effects are mediated through AMPK activation, which shifts fuel preference toward fat oxidation.

However, there are no published human randomized controlled trials on MOTS-c for fat loss specifically. Individual results depend on nutrition, exercise, and metabolic factors.

No completed human safety trials have been published, and there is no peer-reviewed human safety database for MOTS-c. Anecdotal adverse signals include heart palpitations and increased heart rate. Approximately 10% of users may experience adverse reactions, with some reactions being serious.

Individuals with pre-existing cardiac arrhythmia or structural heart disease, active or suspected malignancy, or those who are pregnant or breastfeeding should not use MOTS-c. MOTS-c may interact with medications for diabetes such as metformin.

MOTS-c 10 mg contains the research peptide MOTS-c in lyophilized powder form. It is supplied for research and educational purposes. In research contexts, MOTS-c has been studied as a mitochondrial-derived peptide for its metabolic regulatory properties.

It is not an FDA-approved human pharmaceutical product and is not intended for human use outside approved research contexts.

Frequency of use depends on the specific research or non-medical context. In self-reported protocols, MOTS-c is commonly referenced at 5–10 mg per dose, administered 1–3 times weekly. Typical cycling protocols reference 4–6 weeks on, followed by 2–4 weeks off.

These frequencies are for educational reference only, and no human clinical trial has established an evidence-based dosing schedule.

Post-cycle therapy is not applicable to MOTS-c, as it is not a compound that suppresses the hypothalamic-pituitary-gonadal axis. It is a mitochondrial-derived peptide studied for metabolic regulation.

When MOTS-c is used as part of a broader research protocol that includes anabolic compounds, standard PCT protocols such as those involving Clomixyl or Nolvaxyl would be relevant to those compounds, not to MOTS-c itself.

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome. During metabolic stress such as exercise, it is released and travels to the nucleus to regulate gene expression related to metabolic homeostasis. It activates AMPK, the cell's primary energy sensor, which shifts fuel preference toward fat oxidation, enhances glucose uptake, and supports mitochondrial biogenesis.

Preclinical data from animal models support these effects, but human clinical evidence remains limited.

In self-reported protocols, energy changes have been noted within hours, while metabolic improvements build over 2–4 weeks, with full effects by the end of the first cycle. However, there are no published human clinical trials establishing a time to effect for MOTS-c.

The time required to observe effects depends on the specific outcome being evaluated and individual factors.

There is no single metabolic peptide that is universally best. MOTS-c is unique as a mitochondrial-derived peptide, but other compounds such as GLP-1 agonists have more established human clinical evidence for metabolic effects.

For other peptide-based options in the Kalpa catalog, Ipamorelin 5 mg is a growth hormone secretagogue. The appropriate choice depends on the specific research or clinical context.

MOTS-c 10 mg contains the mitochondrial-derived peptide MOTS-c, which activates AMPK and regulates metabolic gene expression. Ipamorelin 5 mg is a growth hormone secretagogue that stimulates GH release through the ghrelin receptor pathway.

These are different compounds with different mechanisms and research profiles.

The milligram strength of the vial (5 mg) refers to the total amount of MOTS-c in the vial, not the amount administered per dose. The dose administered depends on how the powder is reconstituted and the specific protocol being followed.

It is important to distinguish vial strength from administered dose. A 5 mg vial can be reconstituted with an appropriate volume of diluent to achieve the desired concentration for research or educational purposes.

MOTS-c is not FDA-approved for any medical use. As of July 2026, an FDA advisory panel voted narrowly (7-5, with two abstentions) to recommend MOTS-c be allowed for compounding by pharmacies, though this recommendation does not constitute FDA approval. The regulatory pathway still requires formal rulemaking, which realistically requires 8–12 months for unambiguous legality.

MOTS-c is banned by WADA at all times under Section S4.4 (Metabolic Modulators — AMPK activators). Athletes subject to anti-doping testing should not use MOTS-c in any form.